A systematic review on the use of bortezomib in multiple myeloma patients with renal impairment: What is the published evidence?

Acta Haematologica

Volumn 126, Issue 3, 2011, Pages 163-168

  Piro, Eugenio ^a   Molica, Stefano ^a  

^a PUGLIESE CIACCIO HOSPITAL   (Italy)

Author keywords

Bortezomib; Multiple myeloma; Renal impairment

Indexed keywords

BORTEZOMIB; CREATININE; DEXAMETHASONE; DOXORUBICIN; EPIRUBICIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LENALIDOMIDE; MELPHALAN; PREDNISONE;

CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RELAPSE; CANCER SURVIVAL; CASE CONTROL STUDY; CASE STUDY; COMPETITIVE INHIBITION; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIALYSIS; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY DYSFUNCTION; KIDNEY FAILURE; KIDNEY FUNCTION; MEDICAL LITERATURE; MEDLINE; MULTIPLE MYELOMA; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PHYSICIAN; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REVIEW; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; CREATININE; HUMANS; KIDNEY; MIDDLE AGED; MULTIPLE MYELOMA; PYRAZINES; TREATMENT OUTCOME;

EID: 79960486321     PISSN: 00015792     EISSN: 14219662     Source Type: Journal    
DOI: 10.1159/000328417     Document Type: Review

References (22)

1. Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D, Terpos E, Dimopoulos MA: Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma 2008; 49: 890-895. (Pubitemid 351942741)
2. San-Miguel JF, Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral AL, Esseltine DL, Anderson KC: Efficacy and safety of bortezomib in patients with renal impairment: Results from the APEX phase 3 study. Leukemia 2008; 22: 842-849. (Pubitemid 351552634)
3. Morabito F, Gentile M, Ciolli S, Petrucci MT, Galimberti S, Mele G, Casulli AF, Mannina D, Piro E, Pinotti G, Palmieri S, Catalano L, Callea V, Offidani M, Musto P, Bringhen S, Baldini L, Tosi P, Di Raimondo F, Boccadoro M, Palumbo A, Cavo M: Safety and efficacy of bortezomib-based regimens for multiple myeloma patients with renal impairment: A retrospective study of Italian Myeloma Network GIMEMA. Eur J Haematol 2010; 84: 223-228.
4. Roussou M, Kastritis E, Christoulas D, Migkou M, Gavriatopoulou M, Grapsa I, Psimenou E, Gika D, Terpos E, Dimopoulos MA: Reversibility of renal failure in newly diagnosed patients with multiple myeloma and the role of novel agents. Leuk Res 2010; 34: 1395-1397.
5. Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N: Light chain-induced acute renal failure can be reversed by bortezomib- doxorubicin- dexamethasone in multiple myeloma: Results of a phase II study. J Clin Oncol 2010; 28: 4635-4641.
6. Dimopoulos MA, Roussou M, Gavriatopoulou M, Zagouri F, Migkou M, Matsouka C, Barbarousi D, Christoulas D, Primenou E, Grapsa I, Terpos E, Kastritis E: Reversibility of renal impairment in patients with multiple myeloma treated with bortezomib-based regimens: Identification of predictive factors. Clin Lymphoma Myeloma 2009; 9: 302-306.
7. Bladé J, Sonneveld P, San Miguel JF, Sutherland HJ, Hajek R, Nagler A, Spencer A, Robak T, Cibeira MT, Zhuang SH, Harousseau JL, Orlowski RZ, DOXIL-MMY-3001 Study Investigators: Pegylated liposomal doxorubicin plus bortezomib in relapsed or refractory multiple myeloma: Efficacy and safety in patients with renal function impairment. Clin Lymphoma Myeloma 2008; 8: 352-355.
8. Knauf WU, Otremba B, Overkamp F, Kornacker M: Bortezomib in relapsed multiple myeloma: Results of a non-interventional study by office-based haematologists. Onkologie 2009; 32: 175-180.
9. Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC, SUMMIT/CREST Investigators: Bortezomib in recurrent and/ or refractory multiple myeloma: Initial clinical experience in patients with impaired renal function. Cancer 2005; 103: 1195-1200. (Pubitemid 40328090)
10. Malani AK, Gupta V, Rangineni R: Bortezomib and dexamethasone in previously untreated multiple myeloma associated with renal failure and reversal of renal failure. Acta Haematol 2006; 116: 255-258. (Pubitemid 44795905)
11. Chanan-Khan AA, Kaufman JL, Mehta J, Richardson PG, Miller KC, Lonial S, Munshi NC, Schlossman R, Tariman J, Singhal S: Activity and safety of bortezomib in multiple myeloma patients with advanced renal failure: A multicenter retrospective study. Blood 2007; 109: 2604-2606. (Pubitemid 46425908)
12. Kastritis E, Anagnostopoulos A, Roussou M, Gika D, Matsouka C, Barmparousi D, Grapsa I, Psimenou E, Bamias A, Dimopoulos MA: Reversibility of renal failure in newly diagnosed multiple myeloma patients treated with high dose dexamethasone-containing regimens and the impact of novel agents. Haematologica 2007; 92: 546-549. (Pubitemid 350144300)
13. Onitilo AA, Engel J, Olatosi B, Fagbemi S: Community experience with bortezomib in patients with multiple myeloma. Am J Hematol 2007; 82: 637-639. (Pubitemid 47015288)
14. Ludwig H, Drach J, Graf H, Lang A, Meran JG: Reversal of acute renal failure by bortezomib- based chemotherapy in patients with multiple myeloma. Haematologica 2007; 92: 1411-1414. (Pubitemid 350144160)
15. Li J, Zhou DB, Jiao L, Duan MH, Zhang W, Zhao YQ, Shen T: Bortezomib and dexamethasone therapy for newly diagnosed patients with multiple myeloma complicated by renal impairment. Clin Lymphoma Myeloma 2009; 9: 394-398.
16. Dimopoulos MA, Richardson PG, Schlag R, Khuageva NK, Shpilberg O, Kastritis E, Kropff M, Petrucci MT, Delforge M, Alexeeva J, Schots R, Masszi T, Mateos MV, Deraedt W, Liu K, Cakana A, van de Velde H, San Miguel JF: VMP (Bortezomib, Melphalan, and Prednisone) is active and well tolerated in newly diagnosed patients with multiple myeloma with moderately impaired renal function, and results in reversal of renal impairment: Cohort analysis of the phase III VISTA study. J Clin Oncol 2009; 27: 6086-6093.
17. Qayum A, Aleem A, Al Diab AR, Niaz F, Al Momen AK: Rapid improvement in renal function in patients with multiple myeloma and renal failure treated with bortezomib. Saudi J Kidney Dis Transpl 2010; 21: 63-68.
18. Siniscalchi A, Dentamaro T, Perrotti A, Tatangelo P, de Fabritiis P, Caravita T: Bortezomib- based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with endstage renal disease. Ann Hematol 2010; 89: 821-822.
19. International Myeloma Working Group: Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: A report of the International Myeloma Working Group. Br J Haematol 2003; 121: 749-757.
20. Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand J-P, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau J-L, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BGM, Miguel JS: Renal impairment in patients with multiple myeloma: A consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol 2010; 28: 4976-4984.
21. Uttamsingh V, Lu C, Miwa G, Gan LS: Relative contributions of the five major human cytochromes P450, 1A2, 2C9, 2C19, 2D6, and 3A4, to the hepatic metabolism of the proteasome inhibitor bortezomib. Drug Metab Dispos 2005; 33: 1723-1728. (Pubitemid 41539972)
22. Bringhen S, Larocca A, Rossi D, Cavalli M, Genuardi M, Ria R, Gentili S, Patriarca F, Nozzoli C, Levi A, Guglielmelli T, Benevolo G, Callea V, Rizzo V, Cangialosi C, Musto P, De Rosa L, Liberati AM, Grasso M, Falcone AP, Evangelista A, Cavo M, Gaidano G, Boccadoro M, Palumbo A: Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. Blood 2010; 116: 4745-4753.